<DOC>
	<DOC>NCT01615627</DOC>
	<brief_summary>The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.</brief_summary>
	<brief_title>Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>PAH by standard criteria Treatment with subcutaneous remodulin infusion for at least 3 months, with stable dose for 1 month Pain at infusion site (defined as &gt; 8 on McGill Pain Questionnaire) Known pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Subcutaneous Treprostinil</keyword>
</DOC>